Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study

Abstract Objective This study evaluated the antitumor activity and safety of pemigatinib in previously treated Chinese patients with advanced cholangiocarcinoma and fibroblast growth factor receptor 2 (FGFR2) fusions or rearrangements. Background Pemigatinib provided clinical benefits for previously...

Full description

Bibliographic Details
Main Authors:	Guo‐Ming Shi, Xiao‐Yong Huang, Tian‐Fu Wen, Tian‐Qiang Song, Ming Kuang, Hai‐Bo Mou, Le‐Qun Bao, Hai‐Tao Zhao, Hong Zhao, Xie‐Lin Feng, Bi‐Xiang Zhang, Tao Peng, Yu‐Bao Zhang, Xiang‐Cheng Li, Hong‐Sheng Yu, Yu Cao, Lian‐Xin Liu, Ti Zhang, Wei‐Lin Wang, Jiang‐Hua Ran, Ying‐Bin Liu, Wei Gong, Ming‐Xia Chen, Lian Cao, Yang Luo, Yan Wang, Hui Zhou, Guo‐Huan Yang, Jia Fan, Jian Zhou
Format:	Article
Language:	English
Published:	Wiley 2023-02-01
Series:	Cancer Medicine
Subjects:	antitumor activity cholangiocarcinoma FGFR2 fusions or rearrangements pemigatinib phase II
Online Access:	https://doi.org/10.1002/cam4.5273

Similar Items

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases
by: Jonathan Wadsley, et al.
Published: (2023-08-01)

Pemigatinib in Intrahepatic Cholangiocarcinoma: A Work in Progress
by: Gennaro Gadaleta-Caldarola, et al.
Published: (2022-10-01)

Multifocal serous retinopathy with pemigatinib therapy for metastatic colon adenocarcinoma
by: Oleg Alekseev, et al.
Published: (2021-04-01)

Targeted Therapies in Advanced Cholangiocarcinoma: A Focus on FGFR Inhibitors
by: Alessandro Rizzo
Published: (2021-05-01)

Case report: Pemigatinib-induced retinopathy: a serial examination of subretinal fluid secondary to an FGFR inhibitor
by: Daniel Barmas-Alamdari, et al.
Published: (2024-01-01)

Case Report: Persistent response to combination therapy of pemigatinib, chemotherapy, and immune checkpoint inhibitor in a patient with advanced intrahepatic cholangiocarcinoma
by: Zhuochao Zhang, et al.
Published: (2023-05-01)

FIGHT‐102: A phase 1 study of pemigatinib in Japanese patients with advanced malignancies
by: Yutaka Fujiwara, et al.
Published: (2023-05-01)

Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs
by: Angelica Pace, et al.
Published: (2023-09-01)

FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
by: Anuhya Kommalapati, et al.
Published: (2021-06-01)

Pemigatinib treatment for intrahepatic cholangiocarcinoma with FGFR2 fusion detected by a liquid comprehensive genomic profiling test
by: Shun Ishido, et al.
Published: (2023-07-01)

Targeting the Fibroblast Growth Factor Receptor (FGFR) in Advanced Cholangiocarcinoma: Clinical Trial Progress and Future Considerations
by: Patrick C. Lee, et al.
Published: (2021-04-01)

Targeting FGFR Pathway Is Not an Effective Therapeutic Strategy in Patients with Unselected Metastatic Esophagogastric Cancer Resistant to Trastuzumab
by: Camilla Zecchetto, et al.
Published: (2023-03-01)

The 8p11 myeloproliferative syndrome: Genotypic and phenotypic classification and targeted therapy
by: Taotao Li, et al.
Published: (2022-11-01)

Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants
by: Qianmeng Lin, et al.
Published: (2022-08-01)

Formulation development, optimization and characterization of Pemigatinib-loaded supersaturable self-nanoemulsifying drug delivery systems
by: Muthadi Radhika Reddy, et al.
Published: (2022-11-01)

A comprehensive overview of selective and novel fibroblast growth factor receptor inhibitors as a potential anticancer modality
by: Jain Nem Kumar, et al.
Published: (2024-03-01)

Changing Landscape of Systemic Therapy in Biliary Tract Cancer
by: Edward Woods, et al.
Published: (2022-04-01)

Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system
by: Ying Zhang, et al.
Published: (2023-07-01)

Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration
by: Zi-Rong Chen, et al.
Published: (2023-09-01)

Characterization of FGFR signaling pathway as therapeutic targets for sarcoma patients
by: Wen-Ya Zhou, et al.
Published: (2016-06-01)

FDFT1/FGFR2 rearrangement: A newly identified anlotinib-sensitive FGFR2 variant in cholangiocarcinoma
by: Chunye Huang, et al.
Published: (2022-01-01)

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology
by: Maurizio Capuozzo, et al.
Published: (2022-12-01)

Favorable Outcomes in FGFR Fusion-Positive Cholangiocarcinomas and Evolution on Treatment Noted on Circulating Tumor DNA Liquid Biopsies
by: Pashtoon Murtaza Kasi
Published: (2020-08-01)

FGF2/FGFR1 regulates autophagy in FGFR1-amplified non-small cell lung cancer cells
by: Hong Yuan, et al.
Published: (2017-05-01)

Oncogenic activation revealed by FGFR2 genetic alterations in intrahepatic cholangiocarcinomas
by: Xiaohong Pu, et al.
Published: (2023-11-01)

Biological Significance and Targeting of the FGFR Axis in Cancer
by: Athina-Myrto Chioni, et al.
Published: (2021-11-01)

Recent Advances in Tumor Therapy Targeting FGFR
by: ZHANG Jing, et al.
Published: (2022-02-01)

Trichiasis and dry eye syndrome in two patients on novel fibroblast growth factor receptor inhibitor therapies
by: Kyle B. Vinson, et al.
Published: (2020-09-01)

Progress on the Study of Targeting FGFR in Squamous Non-small Cell Lung Cancer
by: Ming DONG, et al.
Published: (2018-02-01)

Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs
by: Maria-Magdalena Georgescu, et al.
Published: (2021-04-01)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
by: Giovanni Brandi, et al.
Published: (2023-04-01)

Preclinical Evaluation of the FGFR-Family Inhibitor Futibatinib for Pediatric Rhabdomyosarcoma
by: Jerry T. Wu, et al.
Published: (2023-08-01)

A Robust FISH Assay to Detect FGFR2 Translocations in Intrahepatic Cholangiocarcinoma Patients
by: Lei Zhang, et al.
Published: (2023-06-01)

Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis
by: Jinglin Zhang, et al.
Published: (2019-06-01)

Activation of FGFR2 Signaling Suppresses BRCA1 and Drives Triple‐Negative Mammary Tumorigenesis That is Sensitive to Immunotherapy
by: Josh Haipeng Lei, et al.
Published: (2021-11-01)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
by: Daniel Walden, et al.
Published: (2022-08-01)

Genetic variants of FGFR family associated with height, hypertension, and osteoporosis
by: Hye-Won Cho, et al.
Published: (2023-01-01)

Circ_0015756 Aggravates Hepatocellular Carcinoma Development by Regulating FGFR1 via Sponging miR-610
by: Guo W, et al.
Published: (2020-08-01)

Identification and In-Depth Analysis of the Novel FGFR2-NDC80 Fusion in a Cholangiocarcinoma Patient: Implication for Therapy
by: Alexander Scheiter, et al.
Published: (2021-03-01)

FGFR1–4 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer
by: Joanna Moes-Sosnowska, et al.
Published: (2022-09-01)